Law360, New York (July 10, 2007, 12:00 AM ET) -- Biotechnology company Dendreon Corp. said Tuesday that the U.S. Securities and Exchange Commission has opened an informal inquiry into the company's clinical trials for its prostate cancer drug, Provenge.
The inquiry comes on the heels of the U.S. Food and Drug Administration seeking more information from the company on the drug, a move that prompted a handful of shareholder lawsuits.
In a filing with the SEC Tuesday, Dendreon said that the New York Regional Office of the SEC notified the company on Monday that it was...
SEC Looks Into Dendreon Following FDA Disclosure
To view the full article, take a free trial now.
